Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
A2RRP1

UPID:
NBAS_HUMAN

ALTERNATIVE NAMES:
Neuroblastoma-amplified gene protein; Neuroblastoma-amplified sequence

ALTERNATIVE UPACC:
A2RRP1; O95790; Q2VPJ7; Q53TK6; Q86V39; Q8NFY8; Q9Y3W5

BACKGROUND:
The NBAS protein, integral to the NRZ complex, facilitates critical intracellular transport processes and is vital for normal embryonic development. Its alternative identities, Neuroblastoma-amplified gene protein and Neuroblastoma-amplified sequence, reflect its significance in cellular mechanisms.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of NBAS could open doors to potential therapeutic strategies. Its direct involvement in diseases like Short stature, optic nerve atrophy, and Pelger-Huet anomaly, along with Infantile liver failure syndrome 2, underscores its therapeutic relevance.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.